{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:25:05Z","timestamp":1784093105617,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12098-023-04943-9","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T12:02:48Z","timestamp":1702641768000},"page":"724-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Shortened Treatment Regimens for Drug Sensitive TB"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-4305","authenticated-orcid":false,"given":"Kamal Kumar","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"4943_CR1","unstructured":"WHO Operational Handbook on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents [Internet]. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240046832. Accessed on 16 Aug 2023."},{"key":"4943_CR2","unstructured":"Guidelines on Pediatric TB: Central TB Division [Internet]. Available at: https:\/\/tbcindia.gov.in\/index1.php?lang=1&level=2&sublinkid=4200&lid=2848. Accessed on 16 Aug 2023."},{"key":"4943_CR3","unstructured":"World Health Organization. \u2013 2017 - Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care.pdf [Internet]. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255052\/9789241550000-eng.pdf. Accessed on 17 Aug 2023."},{"key":"4943_CR4","first-page":"CD012918","volume":"12","author":"AG Grace","year":"2019","unstructured":"Grace AG, Mittal A, Jain S, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;12:CD012918.","journal-title":"Cochrane Database Syst Rev"},{"key":"4943_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","volume":"14","author":"SS Chiang","year":"2014","unstructured":"Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:947\u201357.","journal-title":"Lancet Infect Dis"},{"key":"4943_CR6","first-page":"3","volume":"7","author":"C Peloquin","year":"2003","unstructured":"Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis. 2003;7:3\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4943_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy026","volume":"67","author":"EM Svensson","year":"2018","unstructured":"Svensson EM, Svensson RJ, Te Brake LHM, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67:34\u201341.","journal-title":"Clin Infect Dis"},{"key":"4943_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5588\/ijtld.17.0498","volume":"22","author":"A Tr\u00e9bucq","year":"2018","unstructured":"Tr\u00e9bucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018;22:17\u201325.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4943_CR9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciu843","volume":"60","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60:1361\u20137.","journal-title":"Clin Infect Dis"},{"key":"4943_CR10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","volume":"188","author":"JH Grosset","year":"2013","unstructured":"Grosset JH, Tyagi S, Almeida DV, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med. 2013;188:608\u201312.","journal-title":"Am J Respir Crit Care Med"},{"key":"4943_CR11","doi-asserted-by":"publisher","first-page":"e00636","DOI":"10.1128\/AAC.00636-18","volume":"62","author":"NC Ammerman","year":"2018","unstructured":"Ammerman NC, Swanson RV, Bautista EM, et al. Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2018;62:e00636\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"4943_CR12","doi-asserted-by":"crossref","unstructured":"Saini V, Ammerman NC, Chang YS, et al. Treatment-shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis. Antimicrob Agents Chemother. 2019;63:e00388-19.","DOI":"10.1128\/AAC.00388-19"},{"key":"4943_CR13","doi-asserted-by":"publisher","first-page":"1602445","DOI":"10.1183\/13993003.02445-2016","volume":"49","author":"M Dalcolmo","year":"2017","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine in multidrug-resistant Tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017;49:1602445.","journal-title":"Eur Respir J"},{"key":"4943_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","volume":"40","author":"G Sotgiu","year":"2012","unstructured":"Sotgiu G, Centis R, D\u2019Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430\u201342.","journal-title":"Eur Respir J"},{"key":"4943_CR15","unstructured":"Centers for Disease Control and Prevention., 2023. Tuberculosis (TB) - Treatment for TB Disease. Available at: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/tbdisease.htm. Accessed on 16 Aug 2023."},{"key":"4943_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2104535","volume":"386","author":"A Turkova","year":"2022","unstructured":"Turkova A, Wills GH, Wobudeya E, et al; SHINE Trial Team. Shorter treatment for nonsevere Tuberculosis in African and Indian children. N Engl J Med. 2022;386:911\u201322.","journal-title":"N Engl J Med"},{"key":"4943_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384:1705\u201318.","journal-title":"N Engl J Med"},{"key":"4943_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7100288","volume":"7","author":"M Muniyandi","year":"2022","unstructured":"Muniyandi M, Karikalan N, Velayutham B, Rajsekar K, Padmapriyadarsini C. Cost effectiveness of a shorter moxifloxacin based regimen for treating drug sensitive tuberculosis in India. Trop Med Infect Dis. 2022;7:288.","journal-title":"Trop Med Infect Dis"},{"key":"4943_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/INF.0000000000000065","volume":"33","author":"R van Toorn","year":"2014","unstructured":"van Toorn R, Schaaf HS, Laubscher JA, van Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33:248\u201352.","journal-title":"Pediatr Infect Dis J"},{"key":"4943_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1542\/peds.2008-1353","volume":"123","author":"GTJ van Well","year":"2009","unstructured":"van Well GTJ, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123:e1-8.","journal-title":"Pediatrics"},{"key":"4943_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac108","volume":"9","author":"G Sulis","year":"2022","unstructured":"Sulis G, Tavaziva G, Gore G, et al. Comparative effectiveness of regimens for drug-susceptible tuberculous meningitis in children and adolescents: a systematic review and aggregate-level data meta-analysis. Open Forum Infect Dis. 2022;9:ofac108.","journal-title":"Open Forum Infect Dis"},{"key":"4943_CR22","unstructured":"ISRCTN - ISRCTN40829906. SURE: Short Intensive Treatment for Children with tuberculous meningitis. Available at: https:\/\/www.isrctn.com\/ISRCTN40829906. Accessed on 16 Aug 2023."},{"key":"4943_CR23","doi-asserted-by":"publisher","first-page":"e1920973","DOI":"10.1001\/jamanetworkopen.2019.20973","volume":"3","author":"M Muniyandi","year":"2020","unstructured":"Muniyandi M, Thomas BE, Karikalan N, et al. Association of Tuberculosis with household catastrophic expenditure in South India. JAMA Netw Open. 2020;3:e1920973.","journal-title":"JAMA Netw Open"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-023-04943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-023-04943-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-023-04943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T03:51:08Z","timestamp":1718164268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-023-04943-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["4943"],"URL":"https:\/\/doi.org\/10.1007\/s12098-023-04943-9","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}